The bar for who should get genetic testing for breast cancer keeps getting lowered, and oncologists have to keep informed about which results should trigger a referral for germline testing, said Nadine Tung, MD, director, Cancer Risk and Prevention Program, Beth Israel Deaconess Medical Center, and associate professor, medicine, Harvard Medical School.
The bar for who should get genetic testing for breast cancer keeps getting lowered, and oncologists have to keep informed about which results should trigger a referral for germline testing, said Nadine Tung, MD, director, Cancer Risk and Prevention Program, Beth Israel Deaconess Medical Center, and associate professor, medicine, Harvard Medical School.
Transcript
How can oncologists determine which patients should have germline testing for hereditary breast cancer?
So, I think when taking care of patients with breast cancer, it is really important to understand which patients have an inherited risk to breast cancer. We've tested for BRCA 1 and 2 mutations for a long time. Now, there are other genes that we know about both with high risk and moderate risk.
It's important to know which of our patients have an inherited mutation, because it informs us about what other cancers they may be at risk for in the future. It also informs us for their relatives who might be at risk and should have different prevention and screening strategies. But increasingly, it's also informing us about what's the optimal treatment to treat that particular breast cancer, whether it is the specific chemotherapy, whether its use of a PARP [poly (ADP-ribose) polymerase] inhibitor. So, it's important to understand who should have genetic testing.
So, the thresholds for who should have genetic testing for breast and ovarian cancer risk genes such as BRCA 1 and 2 is really being lowered consistently. The NCCN [National Comprehensive Cancer Network] guidelines, for example, keep lowering the bar, and it's important for us all to stay informed about that. I think that it is also very important when we're doing more and more tumor testing to identify which of the results from the tumor genomic profiling should trigger a referral for germline testing.
And so, it's important for breast medical oncologists to really understand what is the list of cancer susceptibility genes. And if the tumor profiling has a mutation, a pathogenic variant, or a likely pathogenic variant in one of those cancer risk genes, it really is important to refer the patient for germline genetic testing. I think those are probably the main take home messages.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More